🔗 Share this article World Health Organization Raises Concern Over Acute Lack of Weight-Loss Injections Under one in 10 individuals who could benefit from GLP-1 drugs like Wegovy can access them, states the global health agency as it releases its inaugural guidance on the therapies. Given more than one billion people worldwide currently classified as obese, it is urging broader and more equitable availability to this class of drugs. According to estimates, over two billion will be obese by 2030 unless action is taken. "The latest guidance acknowledges that obesity is a chronic disease that can be managed with thorough and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and distribution challenges are significant obstacles to widespread access to the injections that can aid individuals in losing considerable weight, says the organization. Weight-Loss Drug Shortage Despite the present most optimistic outlook, the supply of such drugs would only suffice for approximately 100 million people – less than 10% of eligible patients, according to the health organization. The recommendation encourages governments and firms to widen availability, by strategies including voluntary licensing. A patent on a key compound – the main component of the drug Wegovy – is scheduled to end in several countries in 2026. How Weight-Loss Jabs Function These medications mimick a natural hormone to reduce digestion speed, suppress the appetite and enhance satiety so people eat less. Individuals commonly start to lose weight after several weeks of beginning the regular doses. Research suggests users may put most of the weight back on after a year of halting the drug, when their normal food cravings come back. Being carrying excess weight elevates your chance for experiencing medical conditions, such as type 2 diabetes, heart disease, brain attack, and certain malignancies. Obesity concerns people in every country and was linked to millions of fatalities worldwide in 2024, per the health agency.
Under one in 10 individuals who could benefit from GLP-1 drugs like Wegovy can access them, states the global health agency as it releases its inaugural guidance on the therapies. Given more than one billion people worldwide currently classified as obese, it is urging broader and more equitable availability to this class of drugs. According to estimates, over two billion will be obese by 2030 unless action is taken. "The latest guidance acknowledges that obesity is a chronic disease that can be managed with thorough and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and distribution challenges are significant obstacles to widespread access to the injections that can aid individuals in losing considerable weight, says the organization. Weight-Loss Drug Shortage Despite the present most optimistic outlook, the supply of such drugs would only suffice for approximately 100 million people – less than 10% of eligible patients, according to the health organization. The recommendation encourages governments and firms to widen availability, by strategies including voluntary licensing. A patent on a key compound – the main component of the drug Wegovy – is scheduled to end in several countries in 2026. How Weight-Loss Jabs Function These medications mimick a natural hormone to reduce digestion speed, suppress the appetite and enhance satiety so people eat less. Individuals commonly start to lose weight after several weeks of beginning the regular doses. Research suggests users may put most of the weight back on after a year of halting the drug, when their normal food cravings come back. Being carrying excess weight elevates your chance for experiencing medical conditions, such as type 2 diabetes, heart disease, brain attack, and certain malignancies. Obesity concerns people in every country and was linked to millions of fatalities worldwide in 2024, per the health agency.